Incidence of Neuroleptic Malignant Syndrome During Antipsychotic Treatment In Children and Youth
September 19, 2024
September 19, 2024
NEW ROCHELLE, New York, Sept. 19 (TNSres) -- Mary Ann Liebert Inc. issued the following news release:
A new study in the peer-reviewed Journal of Child and Adolescent Psychopharmacology estimated the incidence of neuroleptic malignant syndrome (NMS), a potentially fatal adverse effect of antipsychotic treatment, among individuals ages 5-24 years. Click here to read the article now [View article in the link at bottom.].
Wayne Ray, PhD, from the Vanderbilt University Scho . . .
A new study in the peer-reviewed Journal of Child and Adolescent Psychopharmacology estimated the incidence of neuroleptic malignant syndrome (NMS), a potentially fatal adverse effect of antipsychotic treatment, among individuals ages 5-24 years. Click here to read the article now [View article in the link at bottom.].
Wayne Ray, PhD, from the Vanderbilt University Scho . . .